Obesity
Conditions
Keywords
Obesity, Overweight, Synbiotic, Diet, Metabolic dysfunction
Brief summary
Synbiotic is a nutritional supplement that contains both prebiotic and probiotic. Probiotics are beneficial microorganisms, while prebiotics are foods that help the growth of beneficial microorganisms in the gut. In the study, dietary intervention with fruits and vegetables and/or synbiotic supplementation with be administered to Hong Kong Chinese subjects for eight weeks. Changes in the composition and diversity of intestinal microbiota, and markers indicative of obesity, chronic inflammation and metabolic dysfunction will be assessed throughout the whole period. This study will further provide a scientific basis for the intake of synbiotics for reducing the risk of overweight and obesity among Hong Kong Chinese. Furthermore, the results will bridge to further research into the most desirable gut microbiome profile, hence facilitating personalised nutrition for optimal health.
Detailed description
This is an 8-week randomized controlled dietary interventional trial.The objectives of this study include: * To investigate the effects of synbiotic supplementation and/or dietary intervention with fruits and vegetables on gut microbial diversity and composition, and on inflammation, metabolic functioning, overweight and obesity among Hong Kong Chinese * To study whether the changes in gut microbial diversity and composition upon the interventions in Hong Kong Chinese are correlated with metabolic functioning and inflammation, as well as overweight or obesity
Interventions
DIETARY_SUPPLEMENTSynbiotic supplementation
Daily supplementation of synbiotic
BEHAVIORALDietary intervention
Increased fruits and vegetables consumption
Sponsors
Chinese University of Hong Kong
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
20 Years to 95 Years
Healthy volunteers
No
Inclusion criteria
* Waist circumference ≥90cm in men and ≥80cm in women * BMI \>23.0kg/m2
Exclusion criteria
* Practicing dietary restrictions * Using cholesterol-lowering, antihypertensive, anti-inflammatory drugs or Chinese medicines * Consuming laxatives, any gastrointestinal medication, probiotics, prebiotics, synbiotics or antibiotics * Smokers * Alcohol abuser * Currently pregnant or lactating
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Change in body weight at week 8 compared with baseline | Week 0, 8 | Body weight in kilogram |
| Change in Body Mass Index (BMI) at week 8 compared with baseline | Week 0, 8 | BMI = Body weight (in kilograms) divided by square of body height (in meters) |
| Change in body fat percentage at week 8 compared with baseline | Week 0, 8 | Body fat percentage is assessed by bioimpedence |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Change in fasting glucose at week 8 compared with baseline | Week 0, 8 | Fasting glucose in mmol/L |
| Change in fasting insulin at week 8 compared with baseline | Week 0, 8 | Fasting insulin in pmol/L |
| Changes in fasting lipids at week 8 compared with baseline | Week 0, 8 | * Triglycerides in mmol/L * Total cholesterol in mmol/L * HDL-cholesterol in mmol/L |
| Use of 16S rRNA gene sequencing to assess the changes in the composition of the gut microbiota (bacteriome) of stool samples at week 8 compared with baseline | Week 0, 8 | The composition of the gut microbiota (bacteriome) of stool samples is assessed by 16S rRNA gene sequencing |
Countries
Hong Kong
Contacts
STUDY_CHAIRHoi Shan Kwan, PhD
Chinese University of Hong Kong
STUDY_DIRECTORPeter Chi Keung Cheung, PhD
Chinese University of Hong Kong
PRINCIPAL_INVESTIGATORSusana Lauw, MSc
Chinese University of Hong Kong
PRINCIPAL_INVESTIGATORNelson Kei, BSc
Chinese University of Hong Kong
Outcome results
None listed